Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies - Test2 - elhamkhani - TriplyDB

Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies

Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies

http://www.wikidata.org/entity/Q33991470

about

Clinical utility of serum biomarkers in Duchenne muscular dystrophy 204th ENMC International Workshop on Biomarkers in Duchenne Muscular Dystrophy 24-26 January 2014, Naarden, The Netherlands Affinity Proteomics Exploration of Melanoma Identifies Proteins in Serum with Associations to T-Stage and Recurrence.Proteomic profiling of mdx-4cv serum reveals highly elevated levels of the inflammation-induced plasma marker haptoglobin in muscular dystrophy.The EuroBioBank Network: 10 years of hands-on experience of collaborative, transnational biobanking for rare diseases Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy Meeting Report: New Directions in the Biology and Disease of Skeletal Muscle 2014 Serum proteomic profiling reveals fragments of MYOM3 as potential biomarkers for monitoring the outcome of therapeutic interventions in muscular dystrophies.Enhanced Muscular Dystrophy from Loss of Dysferlin Is Accompanied by Impaired Annexin A6 Translocation after Sarcolemmal Disruption.Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study.Increased Levels of Extracellular Microvesicle Markers and Decreased Levels of Endocytic/Exocytic Proteins in the Alzheimer's Disease Brain.Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics.Immunocapture strategies in translational proteomics.Serum Levels of MicroRNA-206 and Novel Mini-STR Assays for Carrier Detection in Duchenne Muscular Dystrophy.Affinity proteomics discovers decreased levels of AMFR in plasma from Osteoporosis patients.Concurrent Label-Free Mass Spectrometric Analysis of Dystrophin Isoform Dp427 and the Myofibrosis Marker Collagen in Crude Extracts from mdx-4cv Skeletal Muscles.Looking Forward to New Therapies: A Personal Perspective on the Translational Landscape for Muscular Dystrophies.Circulating Biomarkers for Duchenne Muscular Dystrophy.Identification of serum protein biomarkers for utrophin based DMD therapy.Muscle-Derived Proteins as Serum Biomarkers for Monitoring Disease Progression in Three Forms of Muscular Dystrophy.A Highlight of Recent Advances in Aptamer Technology and Its Application.Pathoproteomic profiling of the skeletal muscle matrisome in dystrophinopathy associated myofibrosis.Neuroproteomic profiling of human body fluids.Interleukin 1 Receptor-Like 1 Protein (ST2) is a Potential Biomarker for Cardiomyopathy in Duchenne Muscular Dystrophy.Mass spectrometry-based protein analysis to unravel the tissue pathophysiology in Duchenne muscular dystrophy.Progressive muscle proteome changes in a clinically relevant pig model of Duchenne muscular dystrophy.Assessing the translational landscape of myogenic differentiation by ribosome profiling.Reduced serum myostatin concentrations associated with genetic muscle disease progression.Label-free mass spectrometric analysis of the mdx-4cv diaphragm identifies the matricellular protein periostin as a potential factor involved in dystrophinopathy-related fibrosis.Progress toward Gene Therapy for Duchenne Muscular Dystrophy.Comparative mass spectrometric and immunoassay-based proteome analysis in serum of Duchenne muscular dystrophy patients.Non-Invasive Biomarkers for Duchenne Muscular Dystrophy and Carrier Detection.Multiplexed protein profiling by sequential affinity capture.Neo-epitope Peptides as Biomarkers of Disease Progression for Muscular Dystrophies and Other Myopathies.The International Rare Diseases Research Consortium: Policies and Guidelines to maximize impact.MRC Centre Neuromuscular Biobank (Newcastle and London): Supporting and facilitating rare and neuromuscular disease research worldwide.Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne.226th ENMC International Workshop:: Towards validated and qualified biomarkers for therapy development for Duchenne muscular dystrophy 20-22 January 2017, Heemskerk, The Netherlands.Bead-Based and Multiplexed Immunoassays for Protein Profiling via Sequential Affinity Capture.Affinity proteomic profiling of plasma for proteins associated to area-based mammographic breast density.

P2860

Q26751261-D8F97955-BA5D-4D9A-8C45-D7BC88A27E06 Q28611318-7995A66A-AB4C-4B8E-AC18-71DA55C6F63B Q33599603-1C01912C-2238-4C0A-BE63-FC50A1A723B3 Q33675040-9E72FDE4-22AA-4CDD-901C-171F85CAF803 Q34042850-E128F64A-F616-49AF-B344-40B3A587E8EE Q35740280-A2B04259-9332-4B21-8C54-68C50CB758D3 Q35869849-493BDEAE-2307-451B-8A43-619BCF0FDD24 Q35924068-11F92F6A-C0E1-4B91-AB28-6FD0FF29C0C2 Q35987272-087D74F1-9D6D-4939-8843-616E59B3B063 Q35991086-20736746-1957-4F3B-98A3-BF84FB46C1BA Q36135752-33A8A7CF-BADD-4C48-8411-144F95FB2BF5 Q36305436-F1A322B4-7A3A-42A6-99EA-622274758348 Q36519000-359EFC25-E5DD-4B53-A1C8-26E38E7D0D3F Q37210178-8A558935-DF8E-4351-99B2-652A3000B6E9 Q37268854-F83B1EBB-B100-435A-83AC-0E7BECD56569 Q37566483-36F7B800-6A77-4BC1-9761-E301C9B29877 Q37589787-644A7BD4-F3DC-4B15-9E6D-BDC2746F8D7B Q37610530-C06BF282-013F-4B02-BD45-BF292FFF086F Q37676311-3F4D9279-569E-4E4B-BA84-50D4152CDE21 Q38302852-1CD88DE0-740A-436E-844D-51FF1B898930 Q38541697-5A280405-B991-4DDD-A81C-3990411F937C Q38563300-E153F870-3A74-4F0C-B5AC-91566ACFB083 Q38569255-5D998BC5-7341-4DC1-BEE3-FAEF537F068D Q38640186-11EAB4A4-5999-480C-ABC3-216668620BF5 Q38717697-2020A791-526D-4A67-9978-CE1C18B7AC3C Q38820669-0BB21EA0-528C-4289-B8EB-3D180A43DFDC Q38887219-F780825B-E367-46E3-B055-68E19D77BFF6 Q39028061-82429CA7-0804-4A8F-A2F1-32010AA6586B Q39033229-3CDFC397-7640-43DB-8D12-3404EA13187C Q39246797-269D0C20-29F8-4BBB-A03B-8A7A0FCD27B5 Q40198410-4475D4EF-7720-49DB-B567-4DFB63F6A8A8 Q40820281-8FDF1794-65C2-40B9-9728-DA8A75ACDDF2 Q41512772-3571634E-580E-411A-90A1-20CC29E8AA7A Q42363358-01260A59-3DD5-4944-89DA-0946094F87B5 Q45951485-28B6868F-DA8F-453A-8864-9AEF009B39BF Q47103310-0612B8B5-4E32-41E3-B49A-5F33882A3640 Q47115483-D31575AD-8A9A-411F-80B3-35FB1192074B Q48543939-9FE35981-0A5A-40CE-8DD7-DB2CFC6C3027 Q48733575-857C7613-6498-43C1-A529-538042A3ADD4 Q49416704-93A36129-CB02-438E-9F81-686063A74CB8

P2860

Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies

http://www.wikidata.org/entity/Q33991470

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Affinity proteomics within rar ...... arkers of muscular dystrophies

@ast

Affinity proteomics within rar ...... arkers of muscular dystrophies

@en

type

label

Affinity proteomics within rar ...... arkers of muscular dystrophies

@ast

Affinity proteomics within rar ...... arkers of muscular dystrophies

@en

altLabel

Affinity proteomics within rar ...... arkers of muscular dystrophies

@en

prefLabel

Affinity proteomics within rar ...... arkers of muscular dystrophies

@ast

Affinity proteomics within rar ...... arkers of muscular dystrophies

@en

P1433

Q33991470-42F3B724-5B3C-4003-B4E4-0FDB9983A68B

P1476

Q33991470-C372D9EB-DED5-41A0-A337-B18291A876BC

P2093

Q33991470-02171249-D681-48C8-A288-35A04C748B9E

Q33991470-2129A191-0900-4655-9C21-859128F77496

Q33991470-4347B106-D101-4F1F-8773-EA7673A71B77

Q33991470-4AA5B794-6493-4910-A2C5-B150822A6F14

Q33991470-58BAEBE1-CF7D-47E6-9661-1BA5A0B8CFE6

Q33991470-6B3048E8-E5F1-4EBD-A2B3-9627A76EA357

Q33991470-6CBA6128-B373-4097-8270-B3C586C083B8

Q33991470-99F2A38E-1897-40D0-BD5B-85C272E0B713

Q33991470-F166208A-EB1C-4EB0-A3F8-D856C98C67D1

Q33991470-F6DD111F-F77D-4C76-89E2-AD43C51A255D

P2860

Q33991470-049B4904-7A87-491E-A953-DD1D746AB326

Q33991470-0A3677DF-1AF8-4B83-AA1F-A067BFF2383E

Q33991470-10485D89-086F-43C2-9563-A0703B42FCF8

Q33991470-1CB42AE0-819A-49B7-AAD2-5BA67FB6794D

Q33991470-209E037D-61A0-4880-823D-9B8B97EF0839

Q33991470-247CC814-74D5-45F2-A8E7-7A7E1F4B5DD1

Q33991470-2630C005-8C58-4396-91FD-5599A7EBE930

Q33991470-26DBC73C-A2EC-4DC1-83FE-9B71D0C0FF57

Q33991470-276C59A4-C131-4D96-8DC7-8E6C52EFEBC8

Q33991470-2F2DC0A7-04C7-4894-9269-D9451C95987E

P304

Q33991470-EA137A92-452E-4B59-ABB9-FD39E5DE7549

P31

Q33991470-BC4323EB-A08C-4287-BCD9-268C75245652

P356

Q33991470-90FD2490-9D1E-48EF-9CAB-4F552FBE739D

P433

Q33991470-4D4D4C06-DF2F-41F4-86E4-73AA54B961CD

P478

Q33991470-3E917BD1-8741-43F7-BD8A-C5F7DA81AB14

P50

Q33991470-0C3C47F9-5D3B-451D-B7E1-695CBD9C0BC9

Q33991470-1F7CA16A-8779-4702-844B-F6A01FA4B671

Q33991470-2C2B6409-FEAE-48E0-A32A-0A7F45D8CE00

Q33991470-2E430A2F-AB67-46B4-8F6C-D92842EB9D98

Q33991470-3041B54C-1AA9-47BF-9A5B-B62780BBF128

Q33991470-3BDFD8D7-53B1-4C88-B723-0F92C53CD2E1

Q33991470-7DE2C2A0-9752-441D-9031-F81F62E29DB7

Q33991470-8D883674-741E-4B36-8073-ED17CFB5F7BB

Q33991470-99ECE98F-235B-43E0-9BAC-116EAB888558

Q33991470-AA0744F6-84FD-4BAE-8373-765CDA8DCC86

P577

Q33991470-C284913F-9CEA-4BB6-B7EC-59E1787CA2E4

P5875

Q33991470-277026F7-FB14-4694-966F-989F2C1FE2DF

P698

Q33991470-87FD51D7-95C9-45A7-A812-8A357B37BBF9

P921

Q33991470-0B5BD6FC-3101-4B01-91F2-148717F8F332

Q33991470-436F5F25-E305-41C6-B77F-7BB36829EDBB

P932

Q33991470-20BFEE0A-E679-415B-9CE1-8ED231840DB6

P356

P1433

EMBO Molecular Medicine

P1476

Affinity proteomics within rar ...... arkers of muscular dystrophies

@en

P2093

Alessandra Ferlini

http://www.w3.org/2001/XMLSchema#string

Amina Chaouch

http://www.w3.org/2001/XMLSchema#string

Burcu Ayoglu

http://www.w3.org/2001/XMLSchema#string

Elena Schwartz

http://www.w3.org/2001/XMLSchema#string

Francesca Gualandi

http://www.w3.org/2001/XMLSchema#string

Francesco Muntoni

http://www.w3.org/2001/XMLSchema#string

Kate Bushby

http://www.w3.org/2001/XMLSchema#string

Luisa Politano

http://www.w3.org/2001/XMLSchema#string

Monika Hiller

http://www.w3.org/2001/XMLSchema#string

Sebahattin Cirak

http://www.w3.org/2001/XMLSchema#string

P2860

miR-31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy

The human plasma proteome: history, character, and diagnostic prospects

Creatine-kinase- and exercise-related muscle damage implications for muscle performance and recovery

Novel approach to meta-analysis of microarray datasets reveals muscle remodeling-related drug targets and biomarkers in Duchenne muscular dystrophy

Towards a knowledge-based Human Protein Atlas

24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy

Automatic pathway building in biological association networks.

Antibodies for proteomic research: comparison of traditional immunization with recombinant antibody technology.

Serum protein profiling in mice: identification of Factor XIIIa as a potential biomarker for muscular dystrophy.

VennDiagram: a package for the generation of highly-customizable Venn and Euler diagrams in R

P304

918-936

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.15252/EMMM.201303724

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Hanns Lochmüller

Annemieke Aartsma-Rus

Cristina Al-Khalili Szigyarto

Yannick Le Priol

Peter A.C. 't Hoen

P577

2014-06-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263095809

http://www.w3.org/2001/XMLSchema#string

P698

24920607

http://www.w3.org/2001/XMLSchema#string

P921

P932

4119355

http://www.w3.org/2001/XMLSchema#string